Introduction
Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiological entity, described in 1996 [1] , characterized by seizures, headache, confusional state and transient visual deficits, associated generally with high blood pressure and specific magnetic resonance imaging (MRI) findings [bilateral and asymmetrical isointensities or hypointensities in T1, hyperintensities in T2 and fluid attenuation inversion recovery (FLAIR) sequences in the parieto-temporo-occipital regions] [2] . Even though PRES is associated with multiple diseases, its clinical prognosis and radiological outcome is good in both the short and long term, and recurrences are rare [3] ; however, its potential implications in cognitive function or other clinical outcomes have not been addressed. Different entities have been associated with PRES; among autoimmune diseases, systemic lupus erythematosus (SLE) is the most common, although it is important to emphasize that its prevalence is low (< 1%) [4] . However, it should also be considered that PRES could be underdiagnosed in these patients. Up to 50% of SLE patients develop neuropsychiatric manifestations throughout their disease [5] , but currently, PRES is not considered as one of the 19 SLE-associated neuropsychiatric syndromes.
There are different hypotheses regarding the physiopathogenic mechanisms that lead to PRES [i.e. blood-brain barrier disruption, loss of central nervous system (CNS) autoregulation mechanisms, endothelial dysfunction] [2, [6] [7] [8] . Regarding the latter, our group recently described the main independent risk factors associated with the development of PRES in SLE patients, including lymphopenia and dyslipidaemia, which could contribute to endothelial dysfunction [9] . Also, it has been proposed that, in SLE subjects, PRES can be associated either with blood pressure dysregulation or with an immune-mediated aetiology [10] . However, evidence supporting the potential mechanisms associated with PRES is quite scarce. Therefore, we decided to analyse immunological abnormalities that could be part of the physiopathogenic scheme of PRES in SLE patients. The aim of this study was to address whether PRES/SLE patients show a particular serum cytokine profile. We also specifically measured molecules related to systemic endothelial damage [soluble CD40L and vascular endothelial growth factor (VEGF)], as PRESassociated vasogenic oedema may cause hypoxia, which is a strong stimulus for their synthesis [11] .
Methods
We performed a transversal study between January 2012 and March 2015 in a third-level hospital in Mexico City (Instituto Nacional de Ciencias M edicas y Nutrici on, Salvador Zubir an). We included 32 subjects, divided into the following groups: healthy controls (n 5 6), SLE in remission (n 5 6), active SLE (n 5 6) and PRES with SLE (n 5 14). All SLE patients fulfilled ! 4 American College of Rheumatology (ACR) criteria [12] . Remission was considered when the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score was zero and patients had no immunosuppressive treatment during the 12-month period before the blood draw; active SLE patients had SLE-DAI scores ! 6. We excluded subjects with active infections or chronic infections (HIV, viral hepatitis, etc.), pregnancy, SLE-associated CNS activity and the diagnosis of other concomitant autoimmune diseases. We also excluded patients with other altered laboratory parameters or image studies that could explain their neurological symptoms [i.e. serum electrolytes, thyroid function tests, computerized tomography (CT) with findings different from PRES, electroencephalograph (EEG) with epileptogenic focus, cerebrospinal fluid suggestive of meningitis] or with a previous history of SLE-associated CNS activity. PRES diagnosis was considered in patients with the appropriate clinical features (seizures, visual deficit, confusional state or headache) and MRI findings of vasogenic oedema (iso or hypointensity in T1 and hyperintensity in T2/FLAIR), as evaluated by a blinded neuroradiologist. PRES remission was considered when PRES-associated symptoms resolved, regardless of treatment, according to the attending neurologist.
We obtained serum samples from all subjects. All samples were stored frozen until analysis. In patients with PRES, the sample was obtained 36 h from the beginning of symptoms. We analysed cytokine levels using different methods: cytometric bead array [T helper type 1 (Th1), 
Results
All included patients were female. Mean age in the PRES/ SLE group was 33Á3 6 2Á96 years, and did not differ among groups (P 5 0Á29). Mean SLEDAI score was lower in PRES/SLE patients in comparison with patients from the active SLE group (7Á8 6 1Á4 versus 17 6 3Á07, P < 0Á0001). Other demographic, clinical and general laboratory features of SLE patients and healthy controls are shown in Table 1 .
Among patients with PRES/SLE, 35% had lupus nephritis (confirmed by biopsy), with classes IV 1 V (ISN/RPS classification) [13] being the most prevalent; other comorbidities are displayed in Table 2 . Eleven patients (78%) had elevated blood pressure (> 150/90 mmHg) at the time of the event and, in most cases (78%), the main clinical feature was seizures. Mean time to PRES remission was 2Á19 6 0Á58 days. Three patients were classified as 'immunological' PRES [10] , as they were normotensive and received immunosuppressive treatment specifically for the neurological manifestations. Conversely, 11 patients had hypertensive PRES; they were treated with antihypertensives with clinical improvement. When patients in the latter group received immunosuppressive therapy, it was directed against other features of disease activity (mainly renal and haematological). Most MRI findings in subjects with PRES (64%) were considered typical (unilateral or bilateral occipital abnormalities). As shown in Table 2 , there were no statistically significant differences among the SLE groups.
Regarding cytokine levels, PRES/SLE patients had higher serum IL-6 [23Á70 6 9Á37 versus 2Á55 6 0Á65 (healthy controls) versus 2Á04 6 0Á62 (remission SLE) versus 8Á35 6 2Á43 pg/ml (active SLE), P 5 0Á043], as well as IL-10 levels [4Á56 6 1Á40 versus 0Á83 6 0Á09 (healthy controls) versus 1Á00 6 0Á14 (remission SLE) versus 2Á26 6 0Á65 pg/ ml (active SLE), P 5 0Á031] when compared to the other groups, as displayed in Fig. 1 . Furthermore, in this group, there was a positive correlation between both cytokines ( Fig. 2 ; r 5 0Á686, P 5 0Á007). As shown in Table 3 , there were no differences in the other cytokines measured (IL-2, (Table 3 ). There was no association between IL-6 and IL-10 levels and the type of MRI abnormalities (IL-6, v 2 5 0Á062, P 5 1; IL-10, v 2 5 4Á32, P 5 0Á086). We also did not find a correlation between those cytokine levels and time to PRES remission (IL-6 20Á089, P 5 0Á761; IL-10 20Á234, P 5 0Á421).
Discussion
Even though PRES is remarkably associated with SLE [4, 14, 15] , and has even been proposed as one of its neuropsychiatric syndromes [16] , its pathogenesis in these patients is largely unknown. We found a differential serum cytokine profile in patients with PRES and SLE, characterized by high serum IL-6 and IL-10 levels, which could explain some of the disease mechanisms involved. Endothelial dysfunction, with a resultant blood-brain barrier disruption, has been proposed as one of the physiopathogenic mechanisms in PRES [7] . This would be expected in SLE, as endothelial dysfunction and endothelial progenitor cell deficiency have been described in these patients [17] and have been considered to play a role in different complications of the disease, such as accelerated atherosclerosis and thrombotic microangiopathy [18] . Also, our group recently described risk factors associated with the development of PRES in SLE patients, including lymphopenia and dyslipidaemia, which could contribute to endothelial dysfunction [9] . Interestingly, this is not the first association found between low lymphocyte counts and neuropsychiatric disorders in SLE patients [19] .
IL-6, which we found increased significantly in PRES/ SLE patients, could contribute to endothelial damage by inducing the expression of adhesion molecules, which are also considered markers of endothelial activation [7, 20] . The high IL-6 levels we found also agree with previous reports in which IL-6 was increased in cerebrospinal fluid (CSF) from SLE patients with diverse neuropsychiatric syndromes [21, 22] . Furthermore, Asano et al. [23] recently described blood-brain barrier disruption and increased CSF IL-6 levels in SLE patients with diffuse neuropsychiatric symptoms, suggesting that the source of IL-6 is not only intrathecal production, but that it may also enter into the CSF from the systemic circulation through the injured blood-brain barrier. Therefore, increased serum IL-6 could reflect CNS activity. It is noteworthy that we found no correlation between SLEDAI score and IL-6 levels, so it could be hypothesized that this cytokine has certain CNS specificity in SLE patients.
Conversely, IL-10 has been considered classically as an anti-inflammatory cytokine, and has been found recently to exert its anti-inflammatory and neuroprotective actions in the brain [24] [25] [26] . Particularly, it has been shown to inhibit IL-6 and IL-6 receptor expression in murine microglia [25, 27] . Interestingly, both cytokines have signalling Fig. 1. Differential interleukin (IL)-6 and IL-10 serum concentrations among different study groups. Serum IL-6 (a) and IL-10 (b) levels in healthy controls (n 5 6), remission systemic lupus erythematosus (SLE) (n 5 6), active SLE (n 5 6) and posterior reversible encephalopathy syndrome (PRES)/SLE (n 5 14) were measured by cytometric bead array. Bars represent mean 6 standard error of the mean (s.e.m.) of each cytokine concentration in each group. P-values were considered significant at 0Á05. pathways involving signal transducer and activator of transcription-3 (STAT-3) activation, but with different temporal patterns, with IL-10 causing a more sustained phosphorylation and nuclear translocation, leading to the transcription of a specific gene profile and a predominantly anti-inflammatory response [28] . Finally, IL-6 produced by human umbilical cord multipotent stromal cells was found to induce IL-10 expression in monocytes, hence promoting a suppressive phenotype [29] . Therefore, the fact that both these cytokines were increased, and that there was a positive correlation between their levels, may relate to their joint actions over STAT-3 and the induction of IL-10 by IL-6, as well as a potential counter-regulatory action mediated by IL-10 to prevent further damage to endothelial cells [20, 30, 31] .
Finally, VEGF levels were not different among groups, which was a somewhat unexpected finding. VEGF has also been considered to be associated with the development of PRES by increasing adhesion molecule expression and inducing blood-brain barrier permeability [11] , leading to oedema. We did not find higher serum levels in PRES/SLE patients, but it is possible that VEGF synthesis is only increased locally [32] , with direct effects on the brain vasculature, without affecting serum levels.
The main limitation of this study is the small sample size, but it is important to consider that SLE-associated PRES is an extremely rare entity [4, 15, 33] . As cytokine levels were measured at the time of PRES diagnosis, we could not assess whether this profile changed over time and according to clinical features. Also, CSF cytokine levels, which could be more representative of the inflammatory brain scenario, were not measured. However, serum levels might be more feasible to use in routine clinical practice. Finally, we cannot assert that this profile is exclusive to SLE patients with PRES, so prospective studies including other types of neuropsychiatric activity, as well as seizures with other aetiologies, should be performed in order to clarify these issues. Furthermore, studies addressing cytokine levels in patients with non-autoimmune PRES should be performed, in other to determine whether this profile is specific for PRES associated with SLE or if it can be found in patients with PRES from different aetiologies.
In summary, we found a differential serum cytokine profile in PRES/SLE patients. This could partly explain PRES pathogenesis in this group of patients and, by coinciding with findings in other neuropsychiatric manifestations, it also reinforces the fact that PRES could be considered a new neuropsychiatric syndrome in SLE patients. Additionally, serum IL-6 and IL-10 could be used as potential diagnostic markers for this entity. This measurement would be less invasive than CSF cytokine levels. Prospective studies are needed to corroborate our findings and to assess whether this profile is specific for SLE-associated PRES, as well as its longitudinal behaviour. 
